# Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

Source: https://onco.cc/trials/nct07623577/  
OnCo record `nct07623577` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan and bevacizumab in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases is a phase 2, interventional study registered as NCT07623577 by Fudan University, with a registry enrolment figure of 24 participants, started 2026-01-01 and due to reach its primary completion in 2027-01. Interventions recorded: Sacituzumab Tirumotecan (Sac-TMT); bevacizumab. Conditions listed: TNBC; Brain Metastasis. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07623577
- Phase: 2
- Setting: An Open-label, Single-arm, Multi-center Phase II Study of Sacituzumab Tirumotecan (Sac-TMT) Combined With Bevacizumab in Triple-negative Breast Cancer Patients With Brain Metastases
- Sponsor: Fudan University
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT07623577: https://clinicaltrials.gov/study/NCT07623577

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)

---
JSON: https://onco.cc/api/v1/entities/nct07623577.json